AllStripes Collaborates with NIH’s NCATS to Launch Effort in Rare Disease Diagnosis

Rare Daily Staff

AllStripes, a healthcare technology company dedicated to accelerating treatment research for patients with rare diseases, entered into a collaboration with the National Institutes of Health’s National Center for Advancing Translational Sciences to use Allstripes’ real-world evidence platform to improve understanding of the diagnostic journey for rare disease patients.

“The traditional drug development process and approaches for diagnostic intervention are not able to support the unique needs of rare diseases, which affect one in 10 people worldwide. NCATS and AllStripes share a like-minded vision of the urgency to change this paradigm and help bring forward new treatments and diagnostic approaches, faster,” said Nancy Yu, co-founder and chief executive officer of AllStripes. “By leveraging our technology platform, AllStripes and NCATS will collaborate on two studies aimed at identifying opportunities to speed diagnosis and raising awareness of the economic and human cost of rare disease among key stakeholders.”

AllStripes and NCATS will initially launch two studies via AllStripes’ secure and de-identified platform of medical records. The first study will capture data on healthcare utilization in two rare diseases before and during the diagnostic period, with the goal of providing objective data on the cost of rare disease, especially for undiagnosed patients. A second study will capture data on the diagnostic journey in two rare diseases, with the goal of identifying algorithms and opportunities to speed diagnosis. Future studies may also explore the development of novel diagnostic tools to decrease time to diagnosis.

Photo: Nancy Yu, co-founder and chief executive officer of AllStripes